It was announced, it is now official. The National Medicines Agency (ANSM) announced on Thursday that it had taken legal action again on malfunctions of the Marseille IHU during the Raoult era, this time on an unauthorized clinical trial on patients with Covid-19. .
“The ANSM has taken legal action again”, announced a spokesperson to Agence France-Presse (AFP), after analyzing a study on more than 30,000 Covid patients published, among others, by Didier Raoult . This study “can be qualified as RIPH [research involving the human person, editor’s note] category 1” and therefore “should have benefited from a favorable opinion from a committee for the protection of persons and authorization from the ANSM” .
This study “can be qualified as RIPH [research involving the human person, editor’s note] category 1” and therefore “should have benefited from a favorable opinion from a committee for the protection of persons and authorization from the ANSM” . Professor Raoult co-signed in March, with seven co-authors, most of whom still work at the IHU, a “pre-print”, that is to say a version not reviewed by peers, of his study on Covid patients concluding that administration of hydroxychloroquine (or ivermectin) reduced mortality.
In April, the Medicines Agency estimated that the use of hydroxychloroquine “exposes patients to potential adverse effects which can be serious”. Sixteen learned medical societies questioned the authorities at the end of May on a lack of sanctions in the face of the “largest known ‘wild’ therapeutic trial”.
Under pressure from the management of Marseille hospitals, Didier Raoult and the co-authors of the disputed “pre-print” finally decided to withdraw it, Marseille hospitals and the infectious disease specialist said last Friday. Last Wednesday, the Minister of Health, François Braun, brandished the threat of sanctions against these co-authors in the Senate, where he was questioned on “an inertia of the public authorities” in the face of the excesses of the Marseille IHU under the Raoult era. .
